About Vanishing White Matter Disease
Vanishing white matter disease (VWM) is caused by mutations in any of the five EIF2B subunit genes encoding eukaryotic initiation factor 2B, which regulates the integrated stress response. The characteristic feature is progressive rarefaction and cystic degeneration of cerebral white matter that appears nearly absent on MRI. Stress triggers (fever, infection, minor head trauma) cause episodic neurological crises with rapid deterioration, and the disease is often fatal in childhood for early-onset forms.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Vanishing White Matter Disease trials.
EIF2B subunit gene sequencing and protein activity assay are required for diagnosis — document which EIF2B subunit is affected
Brain MRI pattern (diffuse white matter signal change with cystic change and characteristic spectroscopy) is a required enrollment document
Fever and infection prevention protocol during trial participation is critical — trial sites must have VWM emergency management plans
Premature ovarian failure in female patients is a distinct manifestation that may qualify for separate reproductive health sub-studies
Patient Resources
Find recruiting Vanishing White Matter Disease trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Vanishing White Matter Disease. Updated daily.